AI-driven Biomarker Model May Improve Detection of Cancer Cachexia
CHICAGO – A multimodal, artificial intelligence (AI)-driven model that analyzes routinely collected imaging and clinical information led to more...
Search/Filter
Loading...
Adjuvant PD-1 Blockade for Mismatch Repair-deficient Solid Cancers Directed by ctDNA Status Delivers Clinical Benefit
CHICAGO – Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA...
Neoadjuvant PD-1 Blockade in Early-stage Mismatch Repair-deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type
CHICAGO – PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients...
Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-mutated Lung Cancer
CHICAGO – Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced...
Adding Perioperative Pembrolizumab to Standard of Care Improves Outcomes in Patients With Newly Diagnosed Head and Neck Cancer
CHICAGO – Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients...
Richard Pazdur, MD, Honored With the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine
CHICAGO – The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented...
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane- based Chemotherapy
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not...